# OnCo record hepatic-veno-occlusive-disease-after-transplant (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/hepatic-veno-occlusive-disease-after-transplant/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "hepatic-veno-occlusive-disease-after-transplant" ;
  schema:name "Veno-occlusive disease of the liver (sinusoidal obstruction syndrome) after stem cell transplant: prevention, monitoring, diagnosis and defibrotide"@en ;
  schema:alternateName "VOD"@en, "SOS"@en, "SOS/VOD"@en, "hepatic veno-occlusive disease"@en, "sinusoidal obstruction syndrome"@en, "veno-occlusive disease after transplant"@en, "defibrotide treatment"@en, "Baltimore criteria"@en, "modified Seattle criteria"@en, "EBMT VOD criteria"@en, "liver complications after bone marrow transplant"@en ;
  schema:description "Veno-occlusive disease is a liver complication of stem cell transplant in which the smallest blood vessels of the liver become blocked, usually in the first three weeks. Teams look for it every day by weighing the patient, examining the abdomen and checking blood tests, because early treatment is linked with better survival. The medicine used is defibrotide, given with careful fluid management."@en ;
  schema:url <https://onco.cc/protocols/hepatic-veno-occlusive-disease-after-transplant/> ;
  schema:dateModified "2026-11-17"^^xsd:date ;
  onco:related <https://onco.cc/protocols/hct-conditioning-and-engraftment-care/>, <https://onco.cc/protocols/allo-hct-gvhd-prophylaxis/>, <https://onco.cc/protocols/red-cell-and-platelet-transfusion-thresholds/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/pairings/inotuzumab-then-transplant-caution/>, <https://onco.cc/drugs/inotuzumab-ozogamicin/>, <https://onco.cc/drugs/gemtuzumab-ozogamicin/>, <https://onco.cc/drugs/busulfan/>, <https://onco.cc/key-papers/paper-defibrotide-2005-01-blood-2016/> ;
  onco:technologies <https://onco.cc/technologies/allogeneic-hsct/> ;
  onco:drugs <https://onco.cc/drugs/defibrotide/> ;
  onco:terms <https://onco.cc/terms/conditioning-regimen/> .
